Effect of Tranexamic Acid (TXA) on Reduction of Postoperative Blood Transfusion

Description

Tranexamic Acid (TXA) is an antifibrolytic medication used in total hip and knee arthroplasty to reduce the need for intraoperative and postoperative blood transfusions. Limited research is available on its use in hip fracture patients. We hypothesize that the use of TXA preoperatively, perioperatively, and postoperatively will decrease blood loss and need for blood transfusion postoperatively.

Conditions

Hip Fractures

Study Overview

Study Details

Study overview

Tranexamic Acid (TXA) is an antifibrolytic medication used in total hip and knee arthroplasty to reduce the need for intraoperative and postoperative blood transfusions. Limited research is available on its use in hip fracture patients. We hypothesize that the use of TXA preoperatively, perioperatively, and postoperatively will decrease blood loss and need for blood transfusion postoperatively.

Evaluating the Effect of Tranexamic Acid (TXA) on Reduction of Postoperative Blood Transfusion in Hip Fracture Patients

Effect of Tranexamic Acid (TXA) on Reduction of Postoperative Blood Transfusion

Condition
Hip Fractures
Intervention / Treatment

-

Contacts and Locations

Toledo

ProMedica Toledo Hospital, Toledo, Ohio, United States, 43606

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Over the age of 60 years
  • * Hip fracture requiring surgical intervention
  • * Signs consent and agrees to participate
  • * Under the age of 60
  • * Does not sign consent or refuses participation
  • * Known hypersensitivity to tranexamic acid
  • * Multiple acute fractures
  • * Creatinine clearance \<30
  • * History of seizures
  • * Active hormone therapy
  • * History of coagulation abnormality
  • * History of deep vein thrombosis (DVT) or pulmonary embolism (PE) within the last year or history or recurrent DVT/PE
  • * Myocardial infarction (MI) and/or stents within the past year
  • * History of intracranial hemorrhage
  • * Acquired defective color vision
  • * Patients admitted directly to nursing units or surgery without stay in the Emergency Center
  • * Patients who sustain fracture while hospitalized at ProMedica Toledo Hospital

Ages Eligible for Study

60 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Gregory M Georgiadis MD,

Gregory M Georgiadis, MD, PRINCIPAL_INVESTIGATOR, ProMedica Toledo Hospital

Study Record Dates

2025-09-01